Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3636

1.

Rosuvastatin Attenuates acute nephrotoxicity through modulation of oxidative stress in Sprague Dawley rats.

Rasheed HA, Al-Kuraishy HM, Al-Gareeb AI.

J Pak Med Assoc. 2019 Aug;69(Suppl 3)(8):S98-S102.

PMID:
31603887
2.

Rosuvastatin-related rhabdomyolysis causing severe proximal paraparesis and acute kidney injury.

Hussain K, Xavier A.

BMJ Case Rep. 2019 Oct 9;12(10). pii: e229244. doi: 10.1136/bcr-2019-229244.

PMID:
31601550
3.

Expanded table: statins.

[No authors listed]

Med Lett Drugs Ther. 2019 Sep 23;61(1581):e152. No abstract available.

PMID:
31599870
4.

In brief: Ezallor Sprinkle--a new formulation of rosuvastatin.

[No authors listed]

Med Lett Drugs Ther. 2019 Sep 23;61(1581):152. No abstract available.

PMID:
31599869
5.

Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

Lee N, Maeda K, Fukizawa S, Ieiri I, Tomaru A, Akao H, Takeda K, Iwadare M, Niwa O, Masauji T, Yamane N, Kajinami K, Kusuhara H, Sugiyama Y.

Drug Metab Pharmacokinet. 2019 Aug 29. pii: S1347-4367(19)30068-0. doi: 10.1016/j.dmpk.2019.08.004. [Epub ahead of print]

PMID:
31594719
6.

Clinically relevant drug interactions between statins and antidepressants.

Palleria C, Roberti R, Iannone LF, Tallarico M, Barbieri MA, Vero A, Manti A, De Sarro G, Spina E, Russo E.

J Clin Pharm Ther. 2019 Oct 6. doi: 10.1111/jcpt.13058. [Epub ahead of print] Review.

PMID:
31587356
7.

Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly.

Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, Marzolini C.

Clin Pharmacokinet. 2019 Oct 4. doi: 10.1007/s40262-019-00822-9. [Epub ahead of print]

PMID:
31583609
8.

Peripheral polyneuropathy in patients receiving long-term statin therapy.

Özdemir IH, Copkiran Ö, Tıkız H, Tıkız C.

Turk Kardiyol Dern Ars. 2019 Oct;47(7):554-563. doi: 10.5543/tkda.2019.78379.

9.

Rosuvastatin reduces expression of tissue factor through inhibiting RhoA/ROCK pathway to ameliorate atherosclerosis.

Zhou J, Yin G, Yu T, Zhang Y, Tian X, Xia D, Shi L.

Panminerva Med. 2019 Sep 24. doi: 10.23736/S0031-0808.19.03761-3. [Epub ahead of print] No abstract available.

PMID:
31577094
10.

REVERSIBLE NEUROTROPHIC KERATOPATHY ASSOCIATED WITH ROSUVASTATIN THERAPY: A CASE REPORT.

Elnahry AG, Elnahry GA.

J Popul Ther Clin Pharmacol. 2019 Aug 16;26(2):e38-e42. doi: 10.15586/jptcp.v26i2.627.

PMID:
31577084
11.

Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.

Karmaus PWF, Shi M, Perl S, Biancotto A, Candia J, Cheung F, Kotliarov Y, Young N, Fessler MB.

JCI Insight. 2019 Oct 1. pii: 131530. doi: 10.1172/jci.insight.131530. [Epub ahead of print]

12.

Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.

Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H.

Eur J Drug Metab Pharmacokinet. 2019 Sep 30. doi: 10.1007/s13318-019-00577-5. [Epub ahead of print]

PMID:
31571146
13.

Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.

Target Oncol. 2019 Sep 30. doi: 10.1007/s11523-019-00674-0. [Epub ahead of print]

PMID:
31571095
14.

Diagnosis of osteoporosis in statin-treated patients is dose-dependent.

Leutner M, Matzhold C, Bellach L, Deischinger C, Harreiter J, Thurner S, Klimek P, Kautzky-Willer A.

Ann Rheum Dis. 2019 Sep 26. pii: annrheumdis-2019-215714. doi: 10.1136/annrheumdis-2019-215714. [Epub ahead of print]

15.

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.

Csonka D, Bruderer S, Schultz A, Soergel M, Stepanova R, Sabattini G, Perez-Ruixo JJ.

Clin Drug Investig. 2019 Sep 24. doi: 10.1007/s40261-019-00857-7. [Epub ahead of print]

PMID:
31552642
16.

Alterations in Gut Microbiota by Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia.

Kim J, Lee H, An J, Song Y, Lee CK, Kim K, Kong H.

Front Microbiol. 2019 Sep 4;10:1947. doi: 10.3389/fmicb.2019.01947. eCollection 2019.

17.
18.

Asymmetric synthesis of tert-butyl (3R,5S)-6-chloro-3,5-dihydroxyhexanoate using a self-sufficient biocatalyst based on carbonyl reductase and cofactor co-immobilization.

Zhang XJ, Wang WZ, Zhou R, Liu ZQ, Zheng YG.

Bioprocess Biosyst Eng. 2019 Sep 21. doi: 10.1007/s00449-019-02201-x. [Epub ahead of print]

PMID:
31542820
19.

Severe Combined Dyslipidemia With a Complex Genetic Basis.

Le R, Abbas M, McIntyre AD, Hegele RA.

J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619877050. doi: 10.1177/2324709619877050.

20.

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo.

Cho Y, Lee H, Park HK, Choe EY, Wang HJ, Kim RH, Kim Y, Kang ES.

J Atheroscler Thromb. 2019 Sep 13. doi: 10.5551/jat.50039. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center